IPO Date: May 14 to May 16 2025
Listing Date: May 21 2025
a.Capital expenditure towards purchase of new equipment/machineries, etc.b.Capital expenditure towards upgradation of existing manufacturing facility;c.Repayment/prepayment of certain borrowings availed by our Company;d.Funding working capital requirements; ande.General Corporate Purpose
29 Xcelon Ind Park 1 B/h, Intas Pharmaceuticals Vasna Chacharvadi, Sanand
Ahmedabad
Gujarat
382213
9714882929
compliance@accretionpharma.com
http://www.accretionpharma.com
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Rishi Laser has informed that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 28th May, 2026 at 02:00 pm to consider, approve and take on record the Audited Financial Results of the Company for the quarter and year ended 31st March, 2026 and any other matter with the permission of the chair. Further, the Company has already closed the trading window under the SEBI (Prohibition of Insider Trading) Regulations, 2015 with effect from 1st April, 2026 till 48 hours after the dissemination of the Audited Financial Results of the Company for the quarter and year ended 31st March, 2026.
The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, Kitex Garments has informed that the meeting of the Board of Directors of the company is scheduled to be held on Friday, May 29, 2026: a) To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026 and b) To consider and recommend final dividend, if any, on the equity shares of the Company for the financial year ended March 31, 2026. Further, referring to its communication dated March 27, 2026, and pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, and Company’s Code of Conduct for Prevention of Insider Trading, the trading window for dealing in the securities of the Company has been kept closed from April 01, 2026 and shall remain closed till 48 hours after declaration of financial results.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The issue size of Accretion Pharmaceuticals Ltd. IPO is ₹26.25 - 27.62 crore.
The Accretion Pharmaceuticals Ltd. IPO opens for subscription on 2025-05-14 and closes on 2025-05-16.
The price range of Accretion Pharmaceuticals Ltd. IPO is ₹96.00 to ₹101.00.
The lot size of Accretion Pharmaceuticals Ltd. IPO is 1200 shares.
The registrar of Accretion Pharmaceuticals Ltd. IPO is K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.).
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.